Takeda's LIVTENCITY becomes Japan's first approved post-transplant anti-CMV treatment, targeting pUL97 kinase.

Takeda Pharmaceutical has secured approval from Japan's Ministry of Health, Labour and Welfare for its drug LIVTENCITY to treat post-transplant cytomegalovirus (CMV) infections unresponsive to existing therapies. This makes LIVTENCITY the first and only post-transplant anti-CMV treatment approved in Japan, targeting pUL97 kinase and its natural substrates. The approval is based on Phase 3 SOLSTICE trial data.